Record Display for the EPA National Library Catalog


OLS Field Name OLS Field Data
Main Title Letter Form Monsanto Co to Us Epa Regarding Submission of Rat Teratology Studies with Therminol-66 with Attachments.
CORP Author Bio-Dynamics Research and Development Corp., Eugene, OR.; Monsanto Co., Dayton, OH.; Environmental Protection Agency, Washington, DC. Office of Toxic Substances.
Year Published 1990
Report Number 88-900000156
Stock Number OTS0526385
Additional Subjects Toxicology ; Health effects ; Terphenyl ; Reproduction/fertility Effects ; Mammals ; Rats ; Oral ; Gavage ; Teratogenicity ; Toxic substances ; Laboratory animals ; CAS No 26140-60-3 ; CAS No 61788-32-7
Library Call Number Additional Info Location Last
NTIS  OTS0526385 Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy. 03/10/2010
Collation 533p
In a range-finding study, groups of 5 pregnant Charles River COBS CD rats each were administered dimethylacetamide (DMAC) at dose levels of 200, 400, 800, 1800, or 3500 mg/kg/day orally by gavage as a single daily dose on gestation days 6 through 19 at a constant volume of 10 ml/kg bw. Maternal toxicity and death were increased over vehicle (deionized water) controls at dosages of 1800 mg/kg/day and above. Decreased maternal body weight, increased postimplantation loss, and a decrease in the mean number of viable fetuses were seen in the 400 and 800 mg/kg/day groups. No effects on observed parameters were seen in the 200 mg/kg/day group. In the full teratology study, groups of 25 females were administered single daily doses (10 ml/kg volume) of 65, 160, or 400 mg/kg/day orally by gavage on gestation days 6 through 19. A treatment-related decreased mean maternal body weight gain occurred during the treatment period. Fetal body weight was reduced in the 160 mg/kg/day animals, and at 400 mg/kg/day, a significant increase was noted in postimplantation loss, an increase in variations (mainly decreased ossification) which was correlated with fetal weight reduction in this group. Malformations (heart and/or vessel anomalies, cleft palate and anasarca) were increased in the 400 mg/kg/day dose group.